Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769497 | 0.93 | CCNK (0.43) | CCNKCDK12MGLLGAA | |
| SCHEMBL21769475 | 0.93 | THRA (0.42) | MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21769481 | 0.87 | THRA (0.42) | MAPTNPSR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL21769487 | 0.85 | CCNK (0.40) | CCNKCDK12GAA | |
| SCHEMBL21769536 | 0.84 | NPC1 (0.52) | MAPTL3MBTL1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL21769235 | 0.84 | NPSR1 (0.47) | MAPTNPSR1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21769535 | 0.83 | MGLL (0.48) | MGLL | |
| SCHEMBL21769474 | 0.83 | ALDH1A1 (0.43) | MAPTNPSR1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL21769476 | 0.83 | MAPT (0.44) | MAPTNPSR1L3MBTL1MGLLKDM4E | |
| SCHEMBL21440788 | 0.82 | ALDH1A1 (0.48) | NPSR1ALDH1A1SMN1; SMN2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | CCNK 3426/4885CDK12 726/4885MAPT 1188/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | CCNK 3426/4885CDK12 726/4885MAPT 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.